Takeda claims Aurora A kinase inhibitor lead as it takes alisertib into Phase III
This article was originally published in Scrip
Takeda and its oncology arm Millennium have initiated what they claim is the first Phase III trial worldwide with a novel class of oral small molecule kinase inhibitor.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.